S

Shanghai Wanye Enterprises Co Ltd
SSE:600641

Watchlist Manager
Shanghai Wanye Enterprises Co Ltd
SSE:600641
Watchlist
Price: 27.06 CNY 10% Market Closed
Market Cap: ¥24.7B

Shanghai Wanye Enterprises Co Ltd
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shanghai Wanye Enterprises Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai Wanye Enterprises Co Ltd
SSE:600641
Capital Expenditures
-¥290.8m
CAGR 3-Years
-19%
CAGR 5-Years
-74%
CAGR 10-Years
-64%
Longfor Group Holdings Ltd
HKEX:960
Capital Expenditures
-¥124.2m
CAGR 3-Years
26%
CAGR 5-Years
42%
CAGR 10-Years
34%
China Vanke Co Ltd
SZSE:000002
Capital Expenditures
-¥3.2B
CAGR 3-Years
37%
CAGR 5-Years
15%
CAGR 10-Years
-4%
Poly Developments and Holdings Group Co Ltd
SSE:600048
Capital Expenditures
¥2.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Y
Youngor Group Co Ltd
SSE:600177
Capital Expenditures
-¥309.1m
CAGR 3-Years
37%
CAGR 5-Years
17%
CAGR 10-Years
3%
China Merchants Shekou Industrial Zone Holdings Co Ltd
SZSE:001979
Capital Expenditures
-¥3.5B
CAGR 3-Years
17%
CAGR 5-Years
4%
CAGR 10-Years
-9%
No Stocks Found

Shanghai Wanye Enterprises Co Ltd
Glance View

Market Cap
24.7B CNY
Industry
Real Estate

Shanghai Wanye Enterprises Co Ltd has traversed an intriguing journey from its origins, evolving into a dynamic player in several sectors. Rooted in the bustling metropolis of Shanghai, the company navigates multiple industries with a focus on real estate, biotechnology, and high-tech investments. Over the years, Wanye has astutely recognized the potential in blending traditional real estate ventures with new-age biotech innovations. Its real estate arm concentrates primarily on the development and management of commercial and residential properties, leveraging its deep understanding of urban landscapes to maximize asset value. Meanwhile, its interest in biotechnology represents a strategic pivot towards high-growth sectors, signifying an alignment with global trends in health and science innovations. Money-making for Wanye Enterprises involves a sophisticated balance of developing high-demand real estate projects and acquiring stakes in promising biotech start-ups and technological ventures. This dual approach not only diversifies its revenue streams but also mitigates risks associated with market fluctuations in single sectors. The company's real estate segment generates consistent cash flow through property sales and rental income, underwriting its forays into the less predictable biotech sector. Meanwhile, investments in technology and biotechnology hold the potential for substantial returns, underpinning growth through innovations that could revolutionize industries. Through strategic investment, development expertise, and market adaptability, Shanghai Wanye Enterprises Co Ltd effectively harnesses various economic waves, positioning itself as a resilient business entity in China's rapidly evolving economic landscape.

Intrinsic Value
10.09 CNY
Overvaluation 63%
Intrinsic Value
Price ¥27.06
S

See Also

What is Shanghai Wanye Enterprises Co Ltd's Capital Expenditures?
Capital Expenditures
-290.8m CNY

Based on the financial report for Dec 31, 2025, Shanghai Wanye Enterprises Co Ltd's Capital Expenditures amounts to -290.8m CNY.

What is Shanghai Wanye Enterprises Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-64%

Over the last year, the Capital Expenditures growth was -219%. The average annual Capital Expenditures growth rates for Shanghai Wanye Enterprises Co Ltd have been -19% over the past three years , -74% over the past five years , and -64% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett